ArticleAdvanced healthcare materials2026
Folate-Targeted Liposomal Delivery of a Ru(II)-Based Photosensitizer for Photodynamic Tumor Therapy via Pyroptosis Induction.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Pyroptosis has emerged as a promising antitumor strategy offering unique advantages in overcoming apoptosis resistance and activating antitumor immunity. However, the development of drugs capable of achieving spatiotemporally controlled pyroptosis remains a challenge. Herein, we engineered a folate-targeted liposomal nanoplatform to deliver a Ru(II) complex photosensitizer (Ru-Thi@Lipo-FA) for pyroptosis-mediated photodynamic therapy. The Ru(II) complex (Ru-Thi), acting as a photosensitizer, can produce singlet oxygen and superoxide anions and facilitate the photocatalytic oxidation of NADH through multiple mechanisms to kill tumor cells under white light irradiation. Additionally, we encapsulated the complex within folic acid-modified liposomes, which markedly boosted cellular uptake efficiency and tumor targeting, leading to improved therapeutic effects. Mechanistic investigations demonstrated that light-triggered reactive oxygen species generation activates the caspase-3/GSDME-mediated pyroptosis pathway. This study demonstrated a rationally designed, targeted nanoplatform that utilizes a multifunctional Ru(II)-based photosensitizer and induces pyroptosis, providing a viable approach to improve the efficacy of tumor photodynamic therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.